{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:22:25Z","timestamp":1790976145069,"version":"4.1.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent studies have demonstrated that most patients with T-cell acute lymphocytic leukemia (T-ALL) have activating mutations in NOTCH1. We sought to determine whether these mutations are also acquired in mouse models of T-ALL. We sequenced the heterodimerization domain and the PEST domain of Notch1 in our mouse model of TAL1-induced leukemia and found that 74% of the tumors harbor activating mutations in Notch1. Cell lines derived from these tumors undergo G0\/G1 arrest and apoptosis when treated with a \u03b3-secretase inhibitor. In addition, we found activating Notch1 mutations in 31% of thymic lymphomas that occur in mice deficient for various combinations of the H2AX, Tp53, and Rag2 genes. Thus, Notch1 mutations are often acquired as a part of the molecular pathogenesis of T-ALLs that develop in mice with known predisposing genetic alterations. (Blood. 2006;107:781-785)<\/jats:p>","DOI":"10.1182\/blood-2005-06-2553","type":"journal-article","created":{"date-parts":[[2005,9,16]],"date-time":"2005-09-16T00:44:52Z","timestamp":1126831492000},"page":"781-785","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":208,"title":["Activating Notch1 mutations in mouse models of T-ALL"],"prefix":"10.1182","volume":"107","author":[{"given":"Jennifer","family":"O'Neil","sequence":"first","affiliation":[{"name":"From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Howard Hughes Medical Institute, The Children's Hospital, Department of Genetics, Harvard Medical School and The Center for Blood Research, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Calvo","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Howard Hughes Medical Institute, The Children's Hospital, Department of Genetics, Harvard Medical School and The Center for Blood Research, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"McKenna","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Howard Hughes Medical Institute, The Children's Hospital, Department of Genetics, Harvard Medical School and The Center for Blood Research, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Krishnamoorthy","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Howard Hughes Medical Institute, The Children's Hospital, Department of Genetics, Harvard Medical School and The Center for Blood Research, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon C.","family":"Aster","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Howard Hughes Medical Institute, The Children's Hospital, Department of Genetics, Harvard Medical School and The Center for Blood Research, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig H.","family":"Bassing","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Howard Hughes Medical Institute, The Children's Hospital, Department of Genetics, Harvard Medical School and The Center for Blood Research, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick W.","family":"Alt","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Howard Hughes Medical Institute, The Children's Hospital, Department of Genetics, Harvard Medical School and The Center for Blood Research, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Kelliher","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Howard Hughes Medical Institute, The Children's Hospital, Department of Genetics, Harvard Medical School and The Center for Blood Research, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Thomas","family":"Look","sequence":"additional","affiliation":[{"name":"From the Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Howard Hughes Medical Institute, The Children's Hospital, Department of Genetics, Harvard Medical School and The Center for Blood Research, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111814343686600_REF1","doi-asserted-by":"crossref","unstructured":"Ferrando AA, Look AT. Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol.2003;40: 274-280.","DOI":"10.1016\/S0037-1963(03)00195-1"},{"key":"2019111814343686600_REF2","doi-asserted-by":"crossref","unstructured":"Ferrando AA, Herblot S, Palomero T, et al. Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. Blood.2004;103: 1909-1911.","DOI":"10.1182\/blood-2003-07-2577"},{"key":"2019111814343686600_REF3","unstructured":"Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90: German-Austrian-Swiss ALL-BFM Study Group. Blood.2000;95: 3310-3322."},{"key":"2019111814343686600_REF4","doi-asserted-by":"crossref","unstructured":"Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood.2001;97: 1211-1218.","DOI":"10.1182\/blood.V97.5.1211"},{"key":"2019111814343686600_REF5","doi-asserted-by":"crossref","unstructured":"Ferrando AA, Neuberg DS, Dodge RK, et al. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet.2004;363: 535-536.","DOI":"10.1016\/S0140-6736(04)15542-6"},{"key":"2019111814343686600_REF6","doi-asserted-by":"crossref","unstructured":"Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell.2002;1: 75-87.","DOI":"10.1016\/S1535-6108(02)00018-1"},{"key":"2019111814343686600_REF7","doi-asserted-by":"crossref","unstructured":"Ferrando AA, Look AT. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. Semin Hematol.2000;37: 381-395.","DOI":"10.1016\/S0037-1963(00)90018-0"},{"key":"2019111814343686600_REF8","doi-asserted-by":"crossref","unstructured":"Bassing CH, Chua KF, Sekiguchi J, et al. Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc Natl Acad Sci U S A.2002;99: 8173-8178.","DOI":"10.1073\/pnas.122228699"},{"key":"2019111814343686600_REF9","doi-asserted-by":"crossref","unstructured":"Celeste A, Petersen S, Romanienko PJ, et al. Genomic instability in mice lacking histone H2AX. Science.2002;296: 922-927.","DOI":"10.1126\/science.1069398"},{"key":"2019111814343686600_REF10","doi-asserted-by":"crossref","unstructured":"Bassing CH, Suh H, Ferguson DO, et al. Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell.2003;114: 359-370.","DOI":"10.1016\/S0092-8674(03)00566-X"},{"key":"2019111814343686600_REF11","doi-asserted-by":"crossref","unstructured":"Celeste A, Difilippantonio S, Difilippantonio MJ, et al. H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell.2003;114: 371-383.","DOI":"10.1016\/S0092-8674(03)00567-1"},{"key":"2019111814343686600_REF12","doi-asserted-by":"crossref","unstructured":"Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science.1999;284: 770-776.","DOI":"10.1126\/science.284.5415.770"},{"key":"2019111814343686600_REF13","doi-asserted-by":"crossref","unstructured":"Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science.2004;306: 269-271.","DOI":"10.1126\/science.1102160"},{"key":"2019111814343686600_REF14","doi-asserted-by":"crossref","unstructured":"Feldman BJ, Hampton T, Cleary ML. A carboxy-terminal Deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice. Blood.2000;96: 1906-1913.","DOI":"10.1182\/blood.V96.5.1906"},{"key":"2019111814343686600_","doi-asserted-by":"crossref","unstructured":"Hoemann CD, Beaulieu N, Girard L, Rebai N, Jolicoeur P. Two distinct Notch1 mutant alleles are involved in the induction of T-cell leukemia in c-myc transgenic mice. Mol Cell Biol.2000;20: 3831-3842.","DOI":"10.1128\/MCB.20.11.3831-3842.2000"},{"key":"2019111814343686600_","doi-asserted-by":"crossref","unstructured":"Girard L, Jolicoeur P. A full-length Notch1 allele is dispensable for transformation associated with a provirally activated truncated Notch1 allele in Moloney MuLV-infected MMTV(D)\/myc transgenic mice. Oncogene.1998;16: 517-522.","DOI":"10.1038\/sj.onc.1201562"},{"key":"2019111814343686600_REF17","doi-asserted-by":"crossref","unstructured":"Yanagawa S, Lee JS, Kakimi K, Matsuda Y, Honjo T, Ishimoto A. Identification of Notch1 as a frequent target for provirus insertional mutagenesis in T-cell lymphomas induced by leukemogenic mutants of mouse mammary tumor virus. J Virol.2000;74: 9786-9791.","DOI":"10.1128\/JVI.74.20.9786-9791.2000"},{"key":"2019111814343686600_REF18","doi-asserted-by":"crossref","unstructured":"Kelliher MA, Seldin DC, Leder P. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase II\u03b1. EMBO J.1996;15: 5160-5166.","DOI":"10.1002\/j.1460-2075.1996.tb00900.x"},{"key":"2019111814343686600_REF19","doi-asserted-by":"crossref","unstructured":"O'Neil J, Shank J, Cusson N, Murre C, Kelliher M. TAL1\/SCL induces leukemia by inhibiting the transcriptional activity of E47\/HEB. Cancer Cell.2004;5: 587-596.","DOI":"10.1016\/j.ccr.2004.05.023"},{"key":"2019111814343686600_REF20","doi-asserted-by":"crossref","unstructured":"Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell.1996;85: 27-37.","DOI":"10.1016\/S0092-8674(00)81079-X"},{"key":"2019111814343686600_REF21","doi-asserted-by":"crossref","unstructured":"Shinkai Y, Rathbun G, Lam KP, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell.1992;68: 855-867.","DOI":"10.1016\/0092-8674(92)90029-C"},{"key":"2019111814343686600_REF22","doi-asserted-by":"crossref","unstructured":"Deftos ML, Huang E, Ojala EW, Forbush KA, Bevan MJ. Notch1 signaling promotes the maturation of CD4 and CD8 SP thymocytes. Immunity.2000;13: 73-84.","DOI":"10.1016\/S1074-7613(00)00009-1"},{"key":"2019111814343686600_REF23","doi-asserted-by":"crossref","unstructured":"O'Neil J, Ventura JJ, Cusson N, Kelliher M. NF-\u03baB activation in premalignant mouse tal-1\/scl thymocytes and tumors. Blood.2003;102: 2593-2596.","DOI":"10.1182\/blood-2003-01-0090"},{"key":"2019111814343686600_REF24","unstructured":"Shank-Calvo JA, Draheim K, Bhasun M, Kelliher MA. p16Ink4a or p19Arf loss contributes to Tall-induced leukemogenesis in mice. Oncogene. In press."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/2\/781\/1280435\/zh800206000781.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/2\/781\/1280435\/zh800206000781.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T14:33:22Z","timestamp":1586442802000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/2\/781\/131466\/Activating-Notch1-mutations-in-mouse-models-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,15]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,1,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-06-2553","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,15]]}}}